Peripheral Arterial Disease News and Research RSS Feed - Peripheral Arterial Disease News and Research

Vascular events in CML may not be linked to TKI therapy

Vascular events in CML may not be linked to TKI therapy

The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest. [More]
UC San Diego physicians develop potential new therapy for critical limb ischemia

UC San Diego physicians develop potential new therapy for critical limb ischemia

Bioengineers and physicians at the University of California, San Diego have developed a potential new therapy for critical limb ischemia, a condition that causes extremely poor circulation in the limbs and leads to an estimated 230,000 amputations every year in North America and Europe alone to prevent the spread of infection and tissue death. [More]
Unique cardiovascular disease risk calculator for black adults may not be necessary: Study

Unique cardiovascular disease risk calculator for black adults may not be necessary: Study

Although cardiovascular disease risk prediction models are developed with predominantly white populations, application of models to a large black population finds that they work well in black individuals and are not easily improved on, suggesting that a unique risk calculator for black adults may not be necessary, according to a study published online by JAMA Cardiology. [More]
University of Louisville researcher reveals potentially harmful effects of e-cigarettes

University of Louisville researcher reveals potentially harmful effects of e-cigarettes

While e-cigarette use is increasing worldwide, little is known about the health effects e-cigarettes pose for users. A University of Louisville researcher is working to change that status. [More]
Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan. [More]

New research aims to help people suffering from poor blood circulation, reduce aching pains

The University of Salford is looking for volunteers to take part in a new research study that aims to help people who suffer from poor blood circulation to walk without pain. [More]
Review of haemodynamics in stent development shows spiral flow may be key to improving peripheral arterial stent performance

Review of haemodynamics in stent development shows spiral flow may be key to improving peripheral arterial stent performance

Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announces that 'Haemodynamics and Flow Modification Stents for Peripheral Arterial Disease: A Review’, co-authored by VFT’s non-executive Medical Director Graeme Houston, has been published in the Annals of Biomedical Engineering. The paper reviews the importance of haemodynamics in stent development as a method of improving patency and longevity of the stent. [More]

Semler Scientific's revenue up 74% in third quarter 2015

Semler Scientific, Inc., a company that provides diagnostic and testing services to healthcare insurers and physician groups, today reported financial results for the third quarter ended September 30, 2015. [More]
CV risk assessment essential for CML TKI trial design

CV risk assessment essential for CML TKI trial design

The risk and impact of cardiovascular adverse events in long-term users of tyrosine kinase inhibitors for chronic myeloid leukaemia is highlighted in a review published in the Journal of Clinical Oncology. [More]
LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, announced today that the LEADERS FREE clinical trial demonstrated superior safety and efficacy for BioFreedom compared with a bare-metal stent (BMS). [More]
Vascular side effects prevent first-line ponatinib use in chronic phase CML

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment. [More]
Journal of Endovascular Therapy publishes latest update to TASC II guidelines

Journal of Endovascular Therapy publishes latest update to TASC II guidelines

The Journal of Endovascular Therapy, official publication of the INTERNATIONAL SOCIETY OF ENDOVASCULAR SPECIALISTS (ISES), announces that is it today publishing the latest update of the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II), an internationally recognized set of guidelines for the management of patients with peripheral arterial disease (PAD). [More]

Biosensors’ Q1 FY16 revenue reduces US$67.0M compared to US$80.2M in Q1 FY15

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its first fiscal quarter ended 30 June 2015 ("Q1 FY16"). [More]
BioCision, CCT to develop ThawSTAR automated cell thawing system for treatment of diabetic foot ulcers

BioCision, CCT to develop ThawSTAR automated cell thawing system for treatment of diabetic foot ulcers

BioCision, LLC, a leader in advanced technology to improve biological sample handling and standardization, today announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), to accelerate the development of a cell thawing solution based on BioCision’s proprietary ThawSTARÔ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease. [More]
Novel method predicts risk of sudden cardiac death in hemodialysis patients

Novel method predicts risk of sudden cardiac death in hemodialysis patients

A new test has been developed to predict sudden cardiac death in hemodialysis patients in whom such forecasts were previously impossible. The novel method was presented at ICNC 12 by Dr Akiyoshi Hashimoto, a cardiologist at Sapporo Medical University in Japan. The test uses a combination of nuclear medicine, C-reactive protein and electrocardiogram (ECG). [More]
Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the State Intellectual Property Office of China granted a process patent for its novel stem-cell based drug Stempeucel. [More]
Two radiologists win Society of Interventional Radiology Foundation Leaders in Innovation Award

Two radiologists win Society of Interventional Radiology Foundation Leaders in Innovation Award

Two visionaries of interventional radiology were recently awarded the Society of Interventional Radiology Foundation Leaders in Innovation Award. The awards, to Lindsay Machan, M.D., FSIR, an interventional radiologist at Vancouver Hospital, British Columbia, and Kieran J. Murphy, M.D., FSIR, an interventional radiologist at the University of Toronto, both in Canada, were announced March 4 during the society's Annual Scientific Meeting in Atlanta. [More]
Novel technology could improve diagnosis of peripheral arterial disease

Novel technology could improve diagnosis of peripheral arterial disease

Approximately 8 to 12 million people in the United States alone are suffering from peripheral arterial disease (PAD), a common vascular problem that is caused by narrowing of the arteries as a result of plaque buildup. The plaque accumulation leads to an insufficient blood flow to the body's extremities and increases a person's risk for heart attack and stroke by up to six times. PAD is also one of the most serious complications of diabetes. [More]
Biosensors' total revenue decreases 6.06% to of $77.5 million in Q3 FY15

Biosensors' total revenue decreases 6.06% to of $77.5 million in Q3 FY15

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, today announced financial results for the third quarter of its Fiscal Year 2015 ("Q3 FY15") and nine months ended 31 December 2014 ("FY15 nine-month period"). [More]
Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Historic five-year results from the world’s largest clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) were presented last week at the Leipzig Interventional Course, in Germany. The data confirm long-term patency for patients treated with Zilver® PTX®. [More]
Advertisement
Advertisement